Search bioRxiv⌕ Search

Biology subjects

Autelitano, F.

Publications and source records attributed to Autelitano, F..

2 recordsLinked to original sources

PLOD2, a key factor for MRL MSC metabolism and chondroprotective properties

BackgroundInitially discovered for its ability to regenerate ear holes, the MRL mouse has been the subject of multiple research studies aimed at evaluating its ability to regenerate other body tissues and at deciphering the mechanisms underlying it. These enhanced abilities to regenerate, retained in the adult, protect the MRL mouse from degenerative diseases such as osteoarthritis (OA). Here, we hypothesized that MSC derived from the regenerative MRL mouse could be involved in their regenerative potential through the release of pro-regenerative mediators. MethodTo address this hypothesis, we compared the secretome of MRL and BL6 MSC and identified several candidate molecules produced at significantly higher levels by MRL MSC than by BL6 MSC. We selected one candidate and performed functional in vitro assays to evaluate its role on MRL MSC properties including metabolic profile, migration, and chondroprotective effects. Using an experimental model for osteoarthritis (OA) induced by collagenase (CiOA), we assessed its contribution to MRL MSC protection from OA. ResultsAmong the candidate molecules highly expressed by MRL MSC, we focused our attention on procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (PLOD2), coding for the lysyl hydrolase LH2 in charge of post-translational modifications of collagen for its stability and stiffness. PLOD2 is induced by hypoxia-inducible factor 1-alpha (HIF-1a) involved in the regeneration process of adult MRL mice. Plod2 silencing induced a decrease in the glycolytic function of MRL MSC, resulting in the alteration of their migratory and chondroprotective abilities in vitro. In vivo, we showed that plod2 silencing in MRL MSC significantly impaired their capacity to protect mouse from developing OA. ConclusionOur results demonstrate that the chondroprotective and therapeutic properties of MRL MSC in the CiOA experimental model are in part mediated by PLOD2.

cell biology↗

Validation of a small molecule inhibitor of PDE6D-RAS interaction with potent anti-leukemic effects

RAS mutations prevalent in high-risk leukemia have been linked to relapse and chemotherapy resistance. Efforts to directly target RAS proteins have been largely unsuccessful. However, since RAS-mediated transformation is dependent on signaling through the RAS-related C3 botulinum toxin substrate (RAC) small GTPase, we hypothesized that targeting RAC may be an effective therapeutic approach in RAS mutated tumors. Here we describe multiple small molecules capable of inhibiting RAC activation in acute lymphoblastic leukemia cell lines. One of these, DW0254, also demonstrates promising anti-leukemic activity in RAS-mutated cells. Using chemical proteomics and biophysical methods, we identified the hydrophobic pocket of phosphodiester 6 subunit delta (PDE6D), a known RAS chaperone, as a target for this compound. Inhibition of RAS localization to the plasma membrane upon DW0254 treatment is associated with RAC inhibition through a phosphatidylinositol-3-kinase/AKT-dependent mechanism. Our findings provide new insights on the importance of PDE6D-mediated transport for RAS-dependent RAC activation and leukemic cell survival.

cancer biology↗